# OnCo record nct03731260 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03731260/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03731260", "NCT03731260" ;
  schema:name "(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo "@en ;
  schema:alternateName "PIONEER"@en ;
  schema:description "A phase 2 trial of Avapritinib in systemic mastocytosis, run by Blueprint Medicines Corporation, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03731260/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03731260> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2019-04-16" ;
  onco:cancers <https://onco.cc/cancers/systemic-mastocytosis/>, <https://onco.cc/cancers/indolent-systemic-mastocytosis/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/avapritinib/> ;
  onco:companies <https://onco.cc/companies/sanofi/> .